详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases in Gansu Province, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China. [2]Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China. [3]Chemical Synthesis and Pollution Control Key Laboratory of Sichuan Province, College of Chemistry and Chemical Engineering, China West Normal University, Shida Road 1#, Nanchong 637002, China.

出处：

DOI：

ISSN：

关键词： Peptide Fluorescent sensor Zn2+ ions Prostate cancer cells Imaging diagnosis

摘要：

Zinc as a biomarker can be used to diagnose the early stage prostate cancer, while ZIP1 protein, a zinc transporter is significantly down-regulated in prostate cancer cells. This behavior leads to the apparent alteration of the enrichment ability for zinc between early prostate cancer tissues and healthy tissues. This difference inspires us to develop a novel Zn2+ sensor that applies to the clinic diagnosis of early prostate cancer. We designed a tetrapeptide sensor H2L (Dansyl-Gly-Pro-Trp-Gly-NH2) according to the photo-induced electron transfer principle (PET), and it performed adequately in Zn2+ imaging of prostate cell lines. Based on the assessment of Zn2+ enrichment ability, there was distinctly lower Zn2+ concentrate in prostate cancer cell lines than healthy prostate epithelial cells. Furthermore, H2L displayed high sensitivity with a detection limit as low as 49.5 nM, and high specificity for Zn2+ detection. Also the low toxicity and the superior cell permeability of H2L made the imaging of Zn2+ ions detection safe and rapid. We expect that H2L to be a powerful tool for early diagnosis of prostate cancer and a good indicator for the precise resection of cancer tissue during surgery. © 2020 Production and hosting by Elsevier B.V. on behalf of Cairo University.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区综合性期刊

小类 | 2 区综合性期刊

最新[2023]版：

大类 | 1 区

综合性期刊

小类 | 1 区综合性期刊

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases in Gansu Province, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Expression of T-cadherin in prostate cancer and its effect on proliferation of prostate cancer DU145 cells [2]Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. [3]Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue. [4]Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. [5]Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue. [6]T-cadherin基因在前列腺癌组织中的表达及其对前列腺癌细胞DU145增殖的影响 [7]Focal liver lesion diagnosis with deep learning and multistage CT imaging [8]Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells [9]CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression [10]Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway.